Andromeda Surgical Secures Seed Funding to Advance AI‑Powered Robotic Surgery Platform
Andromeda Surgical, a San Francisco‑based startup developing autonomous, AI‑guided robotic systems aimed at enhancing precision and efficiency in surgery, has steadily attracted seed‑stage funding from a range of venture investors since its founding in 2023 as part of Y Combinator’s Summer 2023 cohort. The company’s early‑stage financing reflects growing investor interest in surgical robotics and artificial intelligence applications that can improve surgical outcomes and reduce the learning curve for complex procedures.
Andromeda Surgical has raised funding across multiple seed rounds, with an initial convertible note and subsequent seed VC rounds that collectively brought in capital as the team built its autonomous surgical platform. Estimates indicate the company has raised at least $500,000 in early funding for product development and go‑to‑market activities. These rounds have helped the company progress its technology from concept through early clinical application, including the world’s first robotic‑assisted Holmium Laser Enucleation of the Prostate (HoLEP) procedure using its platform interface.
Among the investors backing Andromeda Surgical is Alumni Ventures, a venture capital firm that supports companies led by founders with proven track records in technology and healthcare. Alumni Ventures has participated in one or more of the company’s seed financings, signaling confidence in the potential of Andromeda’s autonomous surgical systems to transform minimally invasive procedures and empower surgeons to achieve more consistent outcomes.
In addition to Alumni Ventures, Andromeda’s investor roster includes a mix of early‑stage venture firms and startup backers. WestWave Capital, known for investing in technology‑driven startups, provided backing in early seed financings that helped the team refine its AI‑driven guidance system and establish initial operational capabilities. Other venture firms participating in early funding rounds include CoreNest, 468 Capital, BBQ Capital, Hatcher+ and Pioneer Fund, all contributing to the capital base that enabled Andromeda to advance development of its robotic platform. These investors bring diverse experience across AI, robotics and healthcare innovation, providing not only financial support but strategic insight as Andromeda scales.
Another notable investor in Andromeda Surgical is Attack Capital, which invested through its Demo Day Fund as part of its support for startups emerging from accelerator programs like Y Combinator. Attack Capital has highlighted Andromeda’s potential to make complex surgeries more accessible and consistent by combining AI and robotics to empower surgeons, underscoring the belief among its backers that cognitive augmentation and intelligent automation could reshape surgical practice.
The capital raised has underpinned key milestones for Andromeda Surgical, including rapid progress toward clinical implementation and strategic partnerships that broaden the company’s reach. In early 2025, the company announced collaborations with medical technology leaders Richard Wolf and Quanta System to accelerate integration of its robotic platform with industry‑standard imaging and laser technologies, advancing its ability to perform procedures such as robotic‑assisted HoLEP. These alliances, while not direct financial investments, complement venture funding by aligning Andromeda with established players in surgical equipment and enabling co‑development opportunities that can facilitate commercialization.
Andromeda’s trajectory from its seed‑stage financing to clinical milestones illustrates how focused venture capital support can help startups in highly regulated, capital‑intensive sectors like medical robotics move from concept to real‑world use. By attracting a syndicate of early‑stage investors with expertise in AI, robotics and healthcare, Andromeda Surgical is positioning itself to address significant unmet clinical needs and expand its platform beyond initial procedures into broader surgical specialties over time.
As it continues to evolve, the company’s funding story exemplifies the interplay between venture backing, accelerator support and strategic industry collaborations that are increasingly shaping the future of surgical technology and AI‑assisted care.
